CRISPR/Cas9-mediated KLKB1 Gene Editing and Serum Kallikrein Reduction by NTLA-2002 Remains Durable in Humanized Mice Following Liver Regeneration after Partial Hepatectomy

被引:0
|
作者
Walsh, Kathryn [1 ]
Cottingham, Peter [1 ]
Shaw, Cindy [1 ]
Phillips, Jonathan [1 ]
Seitzer, Jessica [1 ]
Blanchard, Chris [1 ]
Gardner, Noah [1 ]
Doshi, Vinita [1 ]
Wood, Kristy [1 ]
Soukamneuth, Samantha [1 ]
Han, Bo [1 ]
Jaligama, Shreelekha [1 ]
Cole, Riley [1 ]
Parthasarathy, Sucharitha [1 ]
Kryukov, Dmitriy [1 ]
Butler, James [1 ]
机构
[1] Intellia Therapeut, Cambridge, MA USA
关键词
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
507
引用
收藏
页码:AB169 / AB169
页数:1
相关论文
共 2 条
  • [1] NTLA-2002: CRISPR/Cas9-mediated gene knockout of KLKB1 to treat hereditary angioedema
    Seitzer, Jessica
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB147 - AB147
  • [2] Updated safety and efficacy of NTLA-2002, a CRISPR/Cas9-based gene editing therapy targeting KLKB1, in a Phase 1 study of patients with hereditary angioedema
    Cohn, D.
    Lindsay, K.
    Gurugama, P.
    Fijen, L. M.
    Petersen, R. S.
    Boiselle, C.
    Xu, Y.
    Carioto-Moreta, M.
    Golden, A.
    Butler, J.
    Shah, M. Y.
    Maag, D.
    Longhurst, H.
    ALLERGY, 2023, 78 : 154 - 154